99mTc-甲氧基异丁基异腈 SPECT/CT 对实性肾脏肿块定性诊断的准确性
回顾性分析2018年9月至2021年10月因实性肾脏肿块行99mTc-甲氧基异丁基异腈 SPECT/CT 的患者影像与临床资料,以组织病理学为参考标准。36个实性肾脏肿块中,SPECT/CT 诊断非关注病变的敏感度和特异度分别为66.7%和89.5%,对比增强 CT 分别为10%和75%。病灶/肾脏平均计数比值以0.46为界值时,敏感度和特异度分别为87.5%和86.67%,显著高于对比增强 CT。
要点
- SPECT/CT 诊断非关注病变的敏感度66.7%、特异度89.5%,对比增强 CT 为10%和75%。
- 病灶/肾脏平均计数比值以0.46为界值时,敏感度87.5%、特异度86.67%。
- 定量评估可进一步提高 SPECT/CT 诊断准确性,或可与视觉判读联合使用。
核心结论
- 99mTc-甲氧基异丁基异腈 SPECT/CT 在鉴别恶性或侵袭性肾肿瘤与良性或惰性肿瘤方面较对比增强 CT 具有增量价值,可能避免过度治疗及其相关并发症。
- 定量评估可进一步提高 SPECT/CT 的诊断准确性,并可与视觉判读联合使用。
研究设计与样本
- 回顾性分析2018年9月至2021年10月因实性肾脏肿块行99mTc-甲氧基异丁基异腈 SPECT/CT 临床检查的患者影像与临床记录。
- 42例患者共62个肾脏肿块行99mTc-甲氧基异丁基异腈 SPECT/CT,其中27例患者(18例男性、9例女性)共36个实性肾脏肿块有组织病理学诊断。
- 20例患者有对比增强 CT 结果;以组织病理学为参考标准,将诊断分为恶性/关注(非嫌色细胞组织学的肾细胞癌)与良性/非关注(包括嫌色细胞肾细胞癌的嗜酸细胞肿瘤及其他良性诊断)。
- 对 SPECT 图像手动分割,获取病灶及邻近肾皮质的最大计数和平均计数以及病灶最大和平均 CT 值(Hounsfield 单位)。
主要发现
- 36个实性肾脏肿块中最常见的单一组织学类型为透明细胞肾细胞癌(13/36;36.1%)。
- 非关注病变中最常见为嗜酸细胞肿瘤(15/36),其中嗜酸细胞瘤为主要组织学类型(n=6)。
- SPECT/CT 诊断非关注病变的敏感度和特异度分别为66.7%和89.5%,对比增强 CT 分别为10%和75%。
- 两组间病灶/肾脏最大计数比值、平均计数比值及病灶最大 CT 值差异有统计学意义(P < 0.05)。
- 病灶/肾脏平均计数比值以0.46为界值时,检测非关注病变的敏感度和特异度分别为87.5%和86.67%,显著高于对比增强 CT。
关键数值与推荐
- SPECT/CT 诊断非关注病变的敏感度66.7%、特异度89.5%;对比增强 CT 敏感度10%、特异度75%。
- 病灶/肾脏平均计数比值以0.46为界值时,检测非关注病变的敏感度87.5%、特异度86.67%,显著高于对比增强 CT。
- 病灶/肾脏最大计数比值、平均计数比值及病灶最大 CT 值在恶性/关注组与良性/非关注组间差异有统计学意义(P < 0.05)。
临床怎么用
- 作者认为,99mTc-甲氧基异丁基异腈 SPECT/CT 在鉴别恶性或侵袭性肾肿瘤与良性或惰性肿瘤方面较对比增强 CT 具有增量价值,可能避免过度治疗及其相关并发症。
- 作者认为,定量评估可进一步提高 SPECT/CT 的诊断准确性,并可与视觉判读联合使用。
局限性
- 作者指出当前关于99mTc-甲氧基异丁基异腈 SPECT/CT 用于实性肾脏肿块定性的文献有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Our objective was to assess the diagnostic accuracy of 99mTc-sestamibi SPECT/CT for characterizing solid renal masses. Methods: Imaging and clinical records of patients who underwent 99mTc-sestamibi SPECT/CT for clinical work-up of their solid renal masses from September 2018 to October 2021 were retrospectively reviewed. Histopathology formed the reference standard, and the diagnoses were categorized as malignant/concerning (renal cell carcinomas [RCCs] other than chromophobe histology) and benign/nonconcerning (oncocytic tumors including chromophobe RCC, other benign diagnoses) to calculate the sensitivity and specificity of 99mTc-sestamibi SPECT/CT and contrast-enhanced CT (ceCT). The clinical reads of the SPECT/CT images were used for visual classification of the lesions. Additionally, the SPECT images were manually segmented to obtain the maximum and mean counts of the lesion and adjacent renal cortex and maximum and mean lesion Hounsfield units. Results: 99mTc-sestamibi SPECT/CT was performed on 42 patients with 62 renal masses. A histopathologic diagnosis was available for 27 patients (18 male, 9 female) with 36 solid renal masses. ceCT findings were available for 20 of these patients. The most commonly identified single histologic type was clear cell RCC (13/36; 36.1%). Oncocytic tumors were the most common group of nonconcerning lesions (15/36), with oncocytoma as the predominant histologic type (n = 6). The sensitivity and specificity of SPECT/CT for diagnosing a nonconcerning lesion were 66.7% and 89.5%, respectively, compared with 10% and 75%, respectively, for ceCT. The lesion-to-kidney ratios for maximum and mean counts and maximum lesion Hounsfield units showed significant differences between the 2 groups (P < 0.05). The lesion-to-kidney mean count ratio at a cutoff of 0.46 showed a sensitivity and specificity of 87.5% and 86.67%, respectively, for detecting nonconcerning lesions, which was significantly higher than that of ceCT. Conclusion: The current literature on the utility of 99mTc-sestamibi SPECT/CT for characterization of solid renal masses is limited. We offer additional evidence of the incremental value of 99mTc-sestamibi SPECT/CT over ceCT for differentiating malignant or aggressive renal tumors from benign or indolent ones, thereby potentially avoiding overtreatment and its associated complications. Quantitative assessment can further increase the diagnostic accuracy of SPECT/CT and may be used in conjunction with visual interpretation.
引用
- Parihar AS, Mhlanga J, Ronstrom C, et al. Diagnostic Accuracy of 99mTc-Sestamibi SPECT/CT for Characterization of Solid Renal Masses. J Nucl Med. 2022. PMID: 35772963. doi:10.2967/jnumed.122.264329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。